Journal article

Effect of ramipril on the incidence of diabetes.

undefined DREAM Trial Investigators, Jackie Bosch, Salim Yusuf, Hertzel C Gerstein, Janice Pogue, Patrick Sheridan, Gilles Dagenais, Rafael Diaz, Alvaro Avezum, Fernando Lanas, Jeffrey Probstfield, George Fodor, Rury R Holman

N Engl J Med | Published : 2006

Abstract

BACKGROUND: Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension. METHODS: In a double-blind, randomized clinical trial with a 2-by-2 factorial design, we randomly assigned 5269 participants without cardiovascular disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and followed them for a median of 3 years. We studied the effects of ramipril on the development of diabetes or death, whichever came first (the primary outcome), and on secondary outcomes, including ..

View full abstract